Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 28Breast Neoplasms 23Neoplasms 21Pancreatic Neoplasms 17Prostatic Neoplasms 16Glioma 16Glioblastoma 16Recurrence 14Leukemia, Myeloid, Acute 14Solid Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Hematologic Neoplasms 8Melanoma 7Lymphoma, B-Cell 7Lymphoma 7Colorectal Neoplasms 7Polycystic Ovary Syndrome 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Advanced Solid Tumors 6Myelodysplastic Syndromes 5Leukemia, Plasma Cell 5Leukemia 5

Interventions

Cobicistat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × BRAF V600E Mutation × Clear all
NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡